1443009-63-9Relevant academic research and scientific papers
Green and reddish-orange light-emitting electrochemical cells using cationic iridium (III) phenanthroline complexes
Moon, Dan Bi,Choe, Young Son
, p. 60 - 68 (2013)
A new series of cationic heteroleptic iridium(III) complexes with phenanthroline based-ancillary ligands, namely, [Ir(ppy)2(dmphen)] PF6, [Ir(ppy)2(dbphen)]PF6 and [Ir(ppy) 2(dpphen)]PF6 (ppy is 2-phenylpyridine, dmphen is 2,9-dimethyl-1,10-phenanthroline, dbphen is 2,9-dibutyl-1,10-phenanthroline, dpphen is 2,9-diphenyl-1,10-phenanthroline and PF6 is hexafluorophosphate) have been synthesized and characterized by various spectroscopic methods. These synthesized complexes were used for the fabrication of single component light-emitting electrochemical cells (LECs). The electroluminescent devices were evaluated on the basis of electroluminescence properties and the effect of substituents on the phenanthroline ligands tune the emission color of the complexes.
Antagonizing STAT3 dimerization with a rhodium(III) complex
Ma, Dik-Lung,Leung, Ka-Ho,Chan, Daniel Shiu-Hin,Chen, Yen-Ting,Wang, Hui-Min David,Liu, Li-Juan,Zhong, Hai-Jing,Leung, Chung-Hang
, p. 9178 - 9182,5 (2014)
Kinetically inert metal complexes have arisen as promising alternatives to existing platinum and ruthenium chemotherapeutics. Reported herein, to our knowledge, is the first example of a substitutionally inert, Group9 organometallic compound as a direct inhibitor of signal transducer and activator of transcription3 (STAT3) dimerization. From a series of cyclometalated rhodium(III) and iridium(III) complexes, a rhodium(III) complex emerged as a potent inhibitor of STAT3 that targeted the SH2 domain and inhibited STAT3 phosphorylation and dimerization. Significantly, the complex exhibited potent anti-tumor activities in an invivo mouse xenograft model of melanoma. This study demonstrates that rhodium complexes may be developed as effective STAT3 inhibitors with potent anti-tumor activity. Saving your skin: A rhodium(III) complex is the first example of a substitutionally inert, Group9 organometallic compound which serves as a direct inhibitor of the signal transducer and activator of transcription3 (STAT3) dimerization. The rhodium(III) complex inhibited STAT3 activity invitro and invivo and showed potent and selective anticancer activity against melanoma cell lines and melanoma xenografts in an invivo mouse model.
